Successful macular hole closure

Article

It is not necessary for patients to remain face-down for more than 24 hours to ensure successful macular hole closure, according to study results published online ahead of print by the British Journal of Ophthalmology.

It is not necessary for patients to remain face-down for more than 24 hours to ensure successful macular hole closure, according to study results published online ahead of print by the British Journal of Ophthalmology.

Judy E. Kim of the Medical College of Wisconsin, United States and colleagues conducted a 15-month multicentre review of patients (n=53; eyes, n=56) undergoing consecutive stage 3 and 4 macular hole surgeries. Mean preoperative visual acuity was 0.74 logMAR (20/100 Snellen). Surgery was not routinely combined with phacoemulsification, but internal limiting membrane (ILM) peeling, using either SF6 or C3F8 gas tamponade, was conducted in 49 eyes. Of the eyes undergoing surgery, 79% had stage 3 macular holes and 70% were phakic.

Macular hole closure was achieved by just one operation in 93% of eyes (n=52). Mean postoperative visual acuity was 0.41 logMAR (20/50 Snellen). The mean follow-up period was 5.2 months.

Therefore the researchers concluded that - since macular hole closure was achieved in the majority of cases by just one operation with only one day of prone positioning - sustained prone positioning is not necessary for successful hole closure.

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
Related Content
© 2024 MJH Life Sciences

All rights reserved.